The FDA's recent warnings on compounded weight-loss drugs stress quality and safety concerns, as these copycat drugs pose risks despite their affordability for patients.
Eli Lilly and Novo Nordisk have sued compounding pharmacies, claiming their copycats are unsafe and fraudulent, highlighting the legal tension in the pharmaceutical industry.
The legal battles between large pharmaceutical companies and compounding pharmacies illustrate a complex landscape, where affordability and safety hang in the balance.
The Outsourcing Facilities Association's letter to the FDA reflects the ongoing conflict over compounding regulations and the pharmaceutical industry's economic interests.
Collection
[
|
...
]